Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;163(4):1095-8.e4.
doi: 10.1016/j.jpeds.2013.04.045. Epub 2013 Jun 6.

Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency

Walter Bonfig  1 , Katharina Molz, Joachim Woelfle, Sabine E Hofer, Berthold P Hauffa, Eckhard Schoenau, Sven Golembowski, Stefan A Wudy, Reinhard W Holl; Diabetes Patienten Verlaufsdocumentationsystem Initiative of the German Working Group for Pediatric Diabetology; German Bundesministerium für Bildung und Forschung Competence Net for Diabetes Mellitus
Affiliations

Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency

Walter Bonfig et al. J Pediatr. 2013 Oct.

Abstract

Objective: To evaluate metabolic consequences of growth hormone (GH) treatment in children with type 1 diabetes.

Study design: This study is an analysis of metabolic changes in 37 patients with childhood-onset GH deficiency and type 1 diabetes, documented in the Diabetes Patienten Verlaufsdocumentationsystem database. Main outcome measures were changes in hemoglobin A1c and daily insulin requirements during GH therapy in children with GH deficiency and type 1 diabetes compared with a large cohort of adolescents with type 1 diabetes.

Results: Thirty-seven patients with type 1 diabetes and a diagnosis of idiopathic GH deficiency after onset of diabetes were compared with 48856 patients with type 1 diabetes. After adjustment for age, sex, duration of diabetes, and migration background, a significant difference in mean daily insulin requirement was seen between the 2 groups (1.0 IU/kg/day in subjects with GH deficiency and type 1 diabetes vs 0.85 IU/kg/day in controls; P < .01) and height-SDS (-2.0 in subjects with GH deficiency and diabetes vs +0.03 in controls; P < .0001). There was no significant between-group difference in hemoglobin A1 concentration, however (8.1% ± 1.4% in patients with GH deficiency and type 1 diabetes vs 8.2% ± 1.7% in those with type 1 diabetes only; P > .05).

Conclusion: An increased daily insulin requirement should be considered in patients with type 1 diabetes treated with GH. With adequate adaptation of insulin dosage, metabolic control is not impaired during GH treatment.

Keywords: DPV; Diabetes Patienten Verlaufsdocumentationsystem; GH; Growth hormone; H-SDS; HbA1c; Height-SDS; Hemoglobin A1c; IGF; Insulin-like growth factor.

PubMed Disclaimer